NasdaqCM:EXASBiotechs
Exact Sciences Milestone In Breast Cancer Testing And What It Means For Valuation
Exact Sciences reports that more than 2 million breast cancer patients have now used its Oncotype DX Breast Recurrence Score test.
The test is used to help personalize treatment decisions and reduce unnecessary chemotherapy in early stage breast cancer.
This milestone highlights broad global adoption of the test in precision cancer care.
For investors watching Exact Sciences, NasdaqCM:EXAS, this milestone sits alongside a current share price of $103.43. The stock has returned 105.5% over...